These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 23106932)

  • 1. Relationship between metabolic syndrome and cognition in patients with schizophrenia.
    Lindenmayer JP; Khan A; Kaushik S; Thanju A; Praveen R; Hoffman L; Cherath L; Valdez G; Wance D
    Schizophr Res; 2012 Dec; 142(1-3):171-6. PubMed ID: 23106932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetes is associated with lower global cognitive function in schizophrenia.
    Takayanagi Y; Cascella NG; Sawa A; Eaton WW
    Schizophr Res; 2012 Dec; 142(1-3):183-7. PubMed ID: 23031192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study.
    Smith RC; Jin H; Li C; Bark N; Shekhar A; Dwivedi S; Mortiere C; Lohr J; Hu Q; Davis JM
    Schizophr Res; 2013 Jan; 143(1):18-24. PubMed ID: 23200554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of work outcome in neuroleptic-resistant schizophrenia and schizoaffective disorder: cognitive impairment and clozapine treatment.
    Kaneda Y; Jayathilak K; Meltzer H
    Psychiatry Res; 2010 Jun; 178(1):57-62. PubMed ID: 20452677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic syndrome and aerobic fitness in patients with first-episode schizophrenia, including a 1-year follow-up.
    Nyboe L; Vestergaard CH; Moeller MK; Lund H; Videbech P
    Schizophr Res; 2015 Oct; 168(1-2):381-7. PubMed ID: 26278336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship of cognitive improvement after cognitive remediation with social functioning in patients with schizophrenia and severe cognitive deficits.
    Lindenmayer JP; Fregenti S; Kang G; Ozog V; Ljuri I; Khan A; Goldring A; McGurk SR
    Schizophr Res; 2017 Jul; 185():154-160. PubMed ID: 28094171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial.
    Stroup S; Appelbaum P; Swartz M; Patel M; Davis S; Jeste D; Kim S; Keefe R; Manschreck T; McEvoy J; Lieberman J
    Schizophr Res; 2005 Dec; 80(1):1-8. PubMed ID: 16182516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive impairments and psychopathological parameters in patients of the schizophrenic spectrum.
    Kontaxaki MI; Kattoulas E; Smyrnis N; Stefanis NC
    Psychiatriki; 2014; 25(1):27-38. PubMed ID: 24739500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of risperidone and aripiprazole on neurocognitive rehabilitation for schizophrenia.
    Matsuda Y; Sato S; Iwata K; Furukawa S; Hatsuse N; Watanabe Y; Anzai N; Kishimoto T; Ikebuchi E
    Psychiatry Clin Neurosci; 2014 Jun; 68(6):425-31. PubMed ID: 24506576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. General and domain-specific neurocognitive impairments in deficit and non-deficit schizophrenia.
    Réthelyi JM; Czobor P; Polgár P; Mersich B; Bálint S; Jekkel E; Magyar K; Mészáros A; Fábián A; Bitter I
    Eur Arch Psychiatry Clin Neurosci; 2012 Mar; 262(2):107-15. PubMed ID: 21792534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Lee SH; Lee YH; Yang SJ; Yoon JS
    Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia.
    Lindenmayer JP; Khan A
    Schizophr Res; 2011 Feb; 125(2-3):267-77. PubMed ID: 20850275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic syndrome and serum homocysteine in patients with bipolar disorder and schizophrenia treated with second generation antipsychotics.
    Vuksan-Ćusa B; Jakovljević M; Sagud M; Mihaljević Peleš A; Marčinko D; Topić R; Mihaljević S; Sertić J
    Psychiatry Res; 2011 Aug; 189(1):21-5. PubMed ID: 21216014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
    Harvey PD; Rabinowitz J; Eerdekens M; Davidson M
    Am J Psychiatry; 2005 Oct; 162(10):1888-95. PubMed ID: 16199835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotic treatment in schizophrenia: the role of computerized neuropsychological assessment.
    Kertzman S; Reznik I; Grinspan H; Weizman A; Kotler M
    Isr J Psychiatry Relat Sci; 2008; 45(2):114-20. PubMed ID: 18982837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia.
    F Egan M; Zhao X; Gottwald R; Harper-Mozley L; Zhang Y; Snavely D; Lines C; Michelson D
    Schizophr Res; 2013 May; 146(1-3):224-30. PubMed ID: 23523692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurocognition, psychopathology, and subjective disturbances in schizophrenia: a comparison between short-term and remitted patients.
    Comparelli A; De Carolis A; Corigliano V; Romano S; Kotzalidis G; Brugnoli R; Tamorri S; Curto M; Tatarelli R; Ferracuti S; Girardi P
    Compr Psychiatry; 2012 Oct; 53(7):931-9. PubMed ID: 22444951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of cognitive and functional improvement and normalization after cognitive remediation in patients with schizophrenia.
    Vita A; Deste G; De Peri L; Barlati S; Poli R; Cesana BM; Sacchetti E
    Schizophr Res; 2013 Oct; 150(1):51-7. PubMed ID: 23998953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.